Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDA) is a dismal disease with an average five-year survival rate of 9%. PDA is the 11th most common cancer in the UK but the fourth largest contributor to cancer related deaths. PDA is characterised by an extensive desmoplastic reaction, which makes up 80% of the tumour volume on average. Here, an abundant and pathological remodelled extracellular matrix increases tissue stiffness and interstitial pressure, which results in decreased therapeutic efficiency. Moreover, the microenvironment contains an abundant fibroblast and myeloid cell infiltrate, which reduces immune surveillance and confers resistance to therapy.
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDA) is a dismal disease with an average five-year survival rate of 9%. PDA is the 11th most common cancer in the UK but the fourth largest contributor to cancer related deaths. PDA is characterised by an extensive desmoplastic reaction, which makes up 80% of the tumour volume on average. Here, an abundant and pathological remodelled extracellular matrix increases tissue stiffness and interstitial pressure, which results in decreased therapeutic efficiency. Moreover, the microenvironment contains an abundant fibroblast and myeloid cell infiltrate, which reduces immune surveillance and confers resistance to therapy.
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity.
Hutton et al. use mass cytometry to chart stromal cells and describe mesenchymal states and lineages in pancreatic ductal adenocarcinoma. CD105 (Eng) expression distinguishes two pancreatic fibroblast lineages with distinct functions. CD105pos fibroblasts are tumour permissive, whereas CD105neg fibroblasts suppress tumour growth in a manner dependent on adaptive immunity.
Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis
Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with a complex microenvironment. Here, we describe how heterocellular Oncostatin M (OSM) - Oncostatin M Receptor (OSMR) signalling reprograms fibroblasts, regulates tumour growth and metastasis.
Annual Scientific Report 2023
This year was a significant period for our Institute as we made the long-anticipated return to the Paterson Building, our brand-new research facility on the Christie NHS Foundation Trust site. Find out how our staff continued to excel in all aspects of Institute life and reconnected with the wider scientific community within the Manchester Cancer Research Centre.